WO2010031832A3 - Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique - Google Patents

Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique Download PDF

Info

Publication number
WO2010031832A3
WO2010031832A3 PCT/EP2009/062101 EP2009062101W WO2010031832A3 WO 2010031832 A3 WO2010031832 A3 WO 2010031832A3 EP 2009062101 W EP2009062101 W EP 2009062101W WO 2010031832 A3 WO2010031832 A3 WO 2010031832A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
thiophene
carboxylic acid
acid derivative
synergistic combinations
Prior art date
Application number
PCT/EP2009/062101
Other languages
English (en)
Other versions
WO2010031832A9 (fr
WO2010031832A2 (fr
Inventor
Tse-I Lin
Oliver Lenz
Original Assignee
Ortho-Mcneil-Janssen Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil-Janssen Pharmaceuticals, Inc filed Critical Ortho-Mcneil-Janssen Pharmaceuticals, Inc
Publication of WO2010031832A2 publication Critical patent/WO2010031832A2/fr
Publication of WO2010031832A3 publication Critical patent/WO2010031832A3/fr
Publication of WO2010031832A9 publication Critical patent/WO2010031832A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison synergique du composé de formule (I) ou d'un de ses sels pharmaceutiquement acceptables, et du composé de formule (II) ou d'un de ses sels pharmaceutiquement acceptables.
PCT/EP2009/062101 2008-09-18 2009-09-18 Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique WO2010031832A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164613.5 2008-09-18
EP08164613 2008-09-18

Publications (3)

Publication Number Publication Date
WO2010031832A2 WO2010031832A2 (fr) 2010-03-25
WO2010031832A3 true WO2010031832A3 (fr) 2010-06-10
WO2010031832A9 WO2010031832A9 (fr) 2011-04-14

Family

ID=40085408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/062101 WO2010031832A2 (fr) 2008-09-18 2009-09-18 Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique

Country Status (1)

Country Link
WO (1) WO2010031832A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
LT2909205T (lt) 2012-10-19 2016-12-27 Bristol-Myers Squibb Company 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
EP2914598B1 (fr) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070974A1 (fr) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (fr) * 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et procedes destines au traitement des infections par flavivirus
WO2007014926A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
WO2007092645A2 (fr) * 2006-02-09 2007-08-16 Schering Corporation Nouvelles combinaisons d'inhibiteurs du vhc et méthodes
WO2007092616A2 (fr) * 2006-02-09 2007-08-16 Schering Corporation Combinaisons comprenant un ou plusieurs inhibiteurs de protéase du vhc et un ou plusieurs inhibiteurs de polymérase du vhc, et méthodes de traitement associées

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (fr) * 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et procedes destines au traitement des infections par flavivirus
WO2007014926A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
WO2007092645A2 (fr) * 2006-02-09 2007-08-16 Schering Corporation Nouvelles combinaisons d'inhibiteurs du vhc et méthodes
WO2007092616A2 (fr) * 2006-02-09 2007-08-16 Schering Corporation Combinaisons comprenant un ou plusieurs inhibiteurs de protéase du vhc et un ou plusieurs inhibiteurs de polymérase du vhc, et méthodes de traitement associées

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEIWERT ET AL: "[439] ADDITIVE TO SYNERGISTIC ANTIVIRAL EFFECTS OF AN NS3/4A PROTEASE INHIBITOR (ITMN-191) AND AN NS5B RNA-DEPENDENT RNA POLYMERASE INHIBITOR (R1479) IN AN HCV REPLICON SYSTEM", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 46, 1 April 2007 (2007-04-01), pages S167, XP022087779, ISSN: 0168-8278 *
WYLES D L; KAIHARA K A; SCHOOLEY R T: "Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, no. 5, May 2008 (2008-05-01), pages 1862 - 1864, XP002507456, ISSN: 0066-4804 *

Also Published As

Publication number Publication date
WO2010031832A9 (fr) 2011-04-14
WO2010031832A2 (fr) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2010031832A3 (fr) Combinaisons synergiques d'un inhibiteur macrocyclique de hcv et d'un dérivé d'acide thiophène-2-carboxylique
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
WO2010105179A3 (fr) Inhibiteurs de bêta-sécrétase
WO2006049835A3 (fr) Derives d'indole et de benzimidazole
WO2007135527A3 (fr) Composés de benzimidazolyle
MY148703A (en) Polycyclic cinnamide derivatives
WO2009016460A8 (fr) Composés pyrazoles
TW200612958A (en) Substituted imidazole derivatives
WO2008086122A3 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5
AU2007306104A1 (en) Hydrobenzamide derivatives as inhibitors of Hsp90
WO2007017728A3 (fr) Nouveaux composes heterocycliques
WO2008155615A3 (fr) Procédé perfectionné pour la préparation d'un antibiotique de la famille des céphalosporines
WO2008048589A3 (fr) Composés et procédés pour le traitement du virus de l'hépatite c
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2008008700A3 (fr) Composés thérapeutiques
WO2009051223A1 (fr) Composition pharmaceutique pour le traitement de la cataracte
WO2007112913A3 (fr) Derives de benzimidazole
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
WO2008021975A3 (fr) Lactames thérapeutiques
WO2008033757A3 (fr) Dérivés d'acétamide 2-(1-oxo-1h-isoquinolin-2-yl)
WO2007146856A3 (fr) Gamma lactames substitués utilisés en tant qu'agents thérapeutiques
WO2008098143A3 (fr) Composés antimicrobiens et leurs procédés d'utilisation
WO2007000655A3 (fr) Nouveaux dérivés de pyrazolopyrimidinone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09783160

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09783160

Country of ref document: EP

Kind code of ref document: A2